Macrolides usage as anti-inflammatory agents in the treatment of community-acquired pneumonia and ventilator-associated pneumonia: a systematic review and meta-analysis
Open Access
- 6 May 2026
- journal article
- review article
- Published by Springer Nature in Systematic Reviews
- Vol. 15 (1)
Abstract
Community-acquired pneumonia (CAP) and ventilator-associated pneumonia (VAP) require effective treatment strategies. In addition to their antimicrobial role, macrolides may have a potential anti-inflammatory role in CAP and VAP. The purpose of this systematic review is to explore the use of macrolides as anti-inflammatory drugs in CAP and VAP and to assess their impact on mortality and hospital length of stay while adhering to treatment guidelines. A comprehensive search was conducted. Inclusion criteria were determined based on the PICOS (Population, Intervention, Comparison, Outcome, and Study Design) framework. The PICOS framework was used to define study eligibility and was not applied as a weighting or scoring system. Only observational studies, non-randomized studies, and randomized controlled trials (RCTs) meeting these criteria were included. A standardized eligibility screening form was employed by three independent reviewers, adhering to the established Cochrane guidelines and utilizing specialized software for analysis. Among 11,960 identified records, 13 studies met the inclusion criteria and underwent qualitative synthesis. Nine studies underwent meta-analysis. Of these, 25% exhibited a low risk of bias, and approximately 50% presented a moderate risk of bias. Meta-analysis showed that macrolide's use was associated with a significant reduction in in-hospital mortality (OR 0.42, 95% CI 0.25-0.71) and post-discharge mortality (OR 0.52, 95% CI 0.31-0.87). A non-significant reduction in length of hospital stay was also observed (MD - 0.68, 95% CI - 1.67 to 0.32). However, the limited number of RCTs reduces the overall quality of the available evidence. Macrolides demonstrate potential anti-inflammatory benefits in CAP and VAP, leading to improved clinical outcomes. However, further well-designed RCTs are needed to strengthen the evidence and confirm these findings. This review was registered in PROSPERO (registration number: CRD42018088203).Keywords
Funding Information
- University of Balamand (RGA/FHS/21-22/008)
This publication has 39 references indexed in Scilit:
- Macrolides as Immunomodulatory Agents2024
- Effect of Combined β-Lactam/Macrolide Therapy on Mortality According to the Microbial Etiology and Inflammatory Status of Patients With Community-Acquired PneumoniaChest, 2019
- Impact of antibiotic therapy in severe community-acquired pneumonia: Data from the Infauci studyJournal of Critical Care, 2018
- Macrolide Use and Neutrophil Function/Cytokine Levels in Hospitalized Patients with Community-Acquired Pneumonia: A Pilot StudyLung, 2015
- GRADE guidelines: 15. Going from evidence to recommendation—determinants of a recommendation's direction and strengthJournal of Clinical Epidemiology, 2013
- Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseasesEuropean Journal of Clinical Pharmacology, 2011
- How Does One Diagnose and Manage Severe Community-Acquired Pneumonia?2010
- Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumoniaIntensive Care Medicine, 2009
- Macrolide immunomodulation of chronic respiratory diseasesCurrent Infectious Disease Reports, 2007
- Effect of Macrolides as Part of Initial Empiric Therapy on Length of Stay in Patients Hospitalized With Community-Acquired PneumoniaArchives of internal medicine (1960), 1999